Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CODX $2.5 Co-Diagnostics finalizes its own unique Coronavirus detection test http://tinyurl.com/vm6e2gj via
@proactive_uk
CODX Co-Diagnostics finalizes its own unique Coronavirus detection test http://tinyurl.com/vm6e2gj via
@proactive_uk
OMG that person is saying the SB Superbowl is cancelled due to coronavirus fears. SB =Super Bowl. It's not true. smh
I noticed boardmarks here went up from 20 to 60 since the Draftkings merger was announced. Stocktwits DEAC thread watchers went from 220 to 2354. That tells me almost everyone trading real stocks in 2020 is over there, not over here.
Not all passengers are good passengers. Sometimes it's good to let a few of the nervous ones leave. Makes for a smoother ride over the long haul.
After the merger closes and everyone gets their shares the original estimate was the market cap would be around $3.3 billion and DEAC Draftkings would have over $500 million dollars in cash. When the merger is completed depending on the stock price that $3.3bn market cap estimate would be higher.
It was bullish. Made DEAC sound like a winner. Pay the $12 and cancel after you read it like I'm going to do.
I don't want to get sued by Barons. There was four of five paragraphs spread out in the article about DEAC Draftkings. Morgan Stanley Analyst projects Draftkings will own at least 15% market share of the entire US mobile sports betting market as sports betting goes Nationwide.
Thats amazing. I paid $12 for the barons trial deal to see the article. At least half of that article is about DEAC Draftkings.
DEAC-Draftkings ... Front page of Barron's : https://www.barrons.com/articles/sports-gambling-will-be-a-huge-opportunity-bet-on-these-stocks-51579915327?mod=hp_HERO?mod=article_signInButton
Imagine if the add the new Draftkings stock ticker on to the sweatshirt.
Yes 1 for 1 share exchange.
$DEAC The online gaming revenue opportunity for DraftKings is between $2.9 billion and $4.7 billion in the U.S. alone, Robins said.
“Our experience in New Jersey, where we are a proven leader in a very competitive market... https://t.co/EzTREXrE4n
Buy one for yourself and buy the other one for your dog. We could use a lucky dog on the team.
1 for 1 share exchange
Immediately thereafter, the currently issued and outstanding shares of DEAC Class A common stock will automatically convert, on a one-for-one basis, into shares of New DraftKings Class A common stock.
Similarly, all of DEAC’s outstanding warrants will become warrants to acquire shares of New DraftKings Class A common stock on the same terms as DEAC’s currently outstanding warrants.
DEACW warrants are too cheap at $3.95 compared to DEAC at $13.50.
DEACW $11.50 strike price
Expires JUNE 2026
Yes today was the first day for the deac options. I still think the deacw warrants with a six year expiration are a much more attractive value proposition. Glad you joined us in deac deacw
Yes today was the first day for the deac options. I still think the deacw warrants with a six year expiration are a much more attractive value proposition.
DEAC Traded over $36 million dollars today. Obvious loading by larger institutional investors..Launching DEAC stock options today opens up more hedging options allowing more aggressive buying
DEAC Traded over $36 million dollars today. Obvious loading by larger institutional investors..Launching DEAC stock options opens up more hedging options allowing more aggressive buying
FCEL $2.20 moving up again heading into next weeks earnings report and CC
XXII Panacea Life Sciences, Inc Closes Series A Investment Round with 22nd Century Group to Expand CBD Operations
Panacea Life Sciences Logo
Panacea Life Sciences Logo
Investment bolsters expansion of Panacea’s CBD manufacturing capabilities and leverages 22nd Century's strengths in packaged-goods and FDA-regulatory affairs.
22nd Century’s investment will allow us to continue to scale our business – including the acceleration of our online and retail sales.”— Leslie Buttorff (CEO of Panacea Life Sciences, Inc.)
GOLDEN, COLORADO, UNITED STATES, January 15, 2020 /EINPresswire.com/ -- Panacea Life Sciences, Inc. (Panacea), a rapidly-growing, vertically-integrated, consumer-facing company operating exclusively in the legal, hemp-derived, CBD product space has received Series A Funding from 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis plant research. 22nd Century’s investments in Panacea over the next twelve to eighteen months are expected to total $24 million in a combination of cash and 22nd Century stock in exchange for Panacea issued convertible debt and preferred equity. 22nd Century has also received a warrant to purchase additional preferred stock of Panacea, which upon full exercise will provide 22nd Century with a controlling equity position in Panacea.
“We are pleased to enter into this long-term, strategic partnership with 22nd Century,” said Leslie Buttorff, Chief Executive Officer of Panacea Life Sciences, Inc. “With a strong team and seed-to-sale operations in place, Panacea is on track to deliver sales growth of over 1,000 percent in 2019, with gross margins over 50%. Our success has been possible because of our focus from day one on producing and marketing the highest-quality, hemp-derived, premium CBD products.
“Our supply chain is complete with track-and-trace capabilities and stringent quality control and testing at every step, from our plant nursery and farm in Colorado’s western slope to our comprehensive extraction, distillation, testing and manufacturing operations located in Golden, Colorado. With state-of-the-art CO2 extraction, chromatography equipment to produce THC-free distillate oil, and product manufacturing lines, we can produce over $1 billion of product per year. This is all driven by our talented, dedicated team and supported by a world-class, custom-developed, SAP-based, Cannabis ERP system that tracks the full chain of custody for every product we sell, which we believe clearly sets us apart from most other companies in the space. 22nd Century’s investment will allow us to continue to scale our business – including the acceleration of our online and retail sales and marketing efforts focused on the Panacea brand,” Buttorff explained.
“After a disciplined and thorough review of the opportunities available to 22nd Century to maximize shareholder value creation, we are pleased to announce the company’s first investment in the legal, hemp/cannabis, consumer packaged goods space,” said Cliff Fleet, Director of 22nd Century Group. “This investment is a major milestone in 22nd Century’s on-going execution of our hemp/cannabis strategic growth plan and offers the opportunity for strong projected shareholder returns.
“Our objective is to build a leading, profitable business in the emerging, legal hemp/cannabis space, and Panacea is an innovative business with a very strong management team who will be able to leverage our leadership in cannabis-plant research, our comprehensive expertise in FDA-regulated spaces, and our leadership team’s deep experience in consumer-packaged goods,” Fleet explained. “The Panacea team has an impressive track record, and I am confident Panacea is very well-positioned for the fast-growing, competitive, and increasingly complex hemp/cannabis marketplace. We are excited to be partnered with Leslie and her team,” said Michael Zercher, 22nd Century’s President and Chief Operating Officer.
The details of the Company’s investment in Panacea are described in a Form 8-K filed with the Securities and Exchange Commission.
About Panacea Life Sciences, Inc.
Panacea Life Sciences, a woman-owned and woman-led company, is dedicated to developing and producing the highest-quality, medically-relevant, legal, THC-free, hemp-derived cannabinoid products for consumers and pets from our 51,000 square foot, state-of-the-art cGMP extraction, manufacturing, testing and fulfillment center located in Golden, Colorado. Panacea operates in every segment of the CBD product value chain, from cultivation to finished goods, with stringent testing protocols employed at every stage of the supply chain from seed-to-sale. Panacea products can be purchased online at https://panacealife.com. For more information about Panacea Life Science’s history and management team visit https://panacealife.com/about/.
About 22nd Century Group, Inc.
22nd Century is a plant biotechnology company focused on technology that allows it to decrease the level of nicotine in tobacco plants and to modify the level of cannabinoids in hemp/cannabis plants through genetic engineering and modern plant breeding. 22nd Century’s growth strategies are focused on meaningful, long-term, shareholder value creation while leveraging its strengths: leadership in cannabis plant research, comprehensive expertise in FDA-regulated spaces, a team with deep experience in consumer-packaged goods, and a strong and flexible balance sheet. To learn more about, 22nd Century please visit www.xxiicentury.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking information, including all statements that are not statements of historical fact regarding the intent, belief or current expectations of 22nd Century Group, Inc., its directors or its officers with respect to the contents of this press release, including but not limited to our future revenue expectations. The words “may,” “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend” and similar expressions and variations thereof are intended to identify forward-looking statements. We cannot guarantee future results, levels of activity or performance with respect to the Company’s investment in Panacea or otherwise. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances, or to reflect the occurrence of unanticipated events. You should carefully review and consider the various disclosures made by us in our annual report on Form 10-K for the fiscal year ended December 31, 2018, filed on March 6, 2019, including the section entitled “Risk Factors”.
Nicholas J. Cavarra
Panacea Life Sciences, Inc.
+1 303-886-5538
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
WDDD Worlds, Inc. Wins Major USPTO Ruling
Press Release | 01/15/2020
PTAB (Patent Trial and Appeal Board) Dismisses All Remaining Inter Partes Review Proceedings Brought Against Worlds, Inc. by Bungie, Inc.
All Patent Claims Returned to Worlds, Inc.
BOSTON, MA / ACCESSWIRE / January 15, 2020 / Worlds, Inc. (OTCQB:WDDD) ("Worlds" or the "Company"), a leading intellectual property developer and licensee of patents related to 3D online virtual worlds, is pleased to announce that on January 14, 2020, the U.S. Patent Trial and Appeal Board (PTAB) issued a Notice that it has dismissed three remaining Petitions for inter partes review, filed by Bungie, Inc., against patents owned by Worlds Inc. in IPR Case Nos. 2015-01264, -01319, and -01321. The Board also vacated its prior Decisions to Institute in these cases, and terminated the inter partes review proceedings initiated by Bungie without issuing final written decisions.
Thom Kidrin, Worlds' Chief Executive Officer, commented, "We are pleased with the PTAB's decision to dismiss Bungie's remaining Petitions for inter partes review against Worlds' patents, thereby reinstating all of our claims in these cases. Worlds has had to endure the legal and financial gauntlet at the PTAB and Federal Circuit for over 4 ½ years while combating the challenges brought by Bungie, but we have ultimately prevailed with important claims intact in each challenged patent, and will return to the District Court in our case against Activision. The PTAB in the end agreed with Worlds' argument that the evidence revealed a relationship between Bungie and Activision, and that relationship prohibited Bungie from challenging Worlds' patents many years after the Activision litigation began. With Bungie's remaining petitions now dismissed, we will move forward and assert our patents against all parties that are infringing upon them."
This Notice followed from the September 7, 2018 decision of the U.S. Court of Appeals for the Federal Circuit, who previously vacated the Board's previous final written decisions in these three cases, and remanded the cases to the Board with instructions to:
consider whether Worlds is estopped from arguing the issue of Real Party in Interest ("RPI") in these proceedings, and
reevaluate the merits of Worlds' argument that Bungie is time-barred from filing petitions for inter partes review based on its relationship with Activision, who has been in litigation with Worlds on the subject patents since 2012.
The relevant statute, 35 U.S.C. § 315(b), prohibits a party from filing a petition for inter partes review more than one year after itself or an RPI was served with a complaint on the subject patent(s). Worlds argued to the Board that if Activision was an RPI to Bungie's petitions, then Bungie was not permitted to file its original petitions in 2015. As of February 22, 2019, this briefing on remand before the Board had been complete, with Worlds awaiting the Board's decision on these questions. Further, Worlds' infringement claims against Activision on these patents have been stayed pending completion of the Board's review.
The Board's Notice states that it has completed its review of the questions posed by the Federal Circuit, and determined both questions in Worlds' favor. The Board determined first that Worlds is not estopped from arguing the RPI on remand, and second that Bungie's Petitions were time-barred and must be dismissed.
The Board's Notice also states that the detailed Termination findings are currently under seal pending the identification of any confidential materials by the parties. However, a public version of the Termination document will be released no later than ten (10) business days from its issue date.
Worlds, Inc.
Worlds, Inc. (OTCQB: WDDD), is a leading intellectual property developer and licensee of patents related to 3D online virtual worlds. The Company has a portfolio of 10 US patents for multi-server technology for 3D applications. The earliest of these patents issued on an application filed November 12, 1996. A provisional patent application, serial number 60/020,296, was filed on November 13, 1995. These patents are related to each other and disclose and claim systems and methods for enabling users to interact in a virtual space.
For additional information about Worlds, Inc., please visit: www.Worlds.com.
Forward-Looking Statements
This release contains certain forward-looking statements and information relating to Worlds Inc. that are based on the beliefs of Worlds' management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "estimated," "should," "preparing," "expected" or words of a similar nature. The Company does not intend to update these forward-looking statements.
Contacts:
Accentuate PR
Julie Shepherd
847-275-3643
Julie@accentuatepr.com
Corporate
617-725-8900
info@worlds.com
SOURCE: Worlds Inc.
View source version on accesswire.com:
https://www.accesswire.com/573153/Worlds-Inc-Wins-Major-USPTO-Ruling
1 for 1 share exchange
Immediately thereafter, the currently issued and outstanding shares of DEAC Class A common stock will automatically convert, on a one-for-one basis, into shares of New DraftKings Class A common stock.
Similarly, all of DEAC’s outstanding warrants will become warrants to acquire shares of New DraftKings Class A common stock on the same terms as DEAC’s currently outstanding warrants.
You never got back to me with those dollar amounts.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=153274351
40m DEAC 13.9 million DEACW
DEAC trades on nasdaq not on otcmarkets. 40 million OS
The number of shares of Class A common stock of New DraftKings being registered includes (i) 40,000,000 shares of DEAC Class A common stock that were sold pursuant to DEAC’s Registration Statement on Form S-1 (File No. 333-230815) as part of the units in DEAC’s initial public offering (the “public shares”), all of which will automatically convert into shares of New DraftKings Class A common stock in the reincorporation and the business combination
Turns out you can write a very sad song with Only TWO Notes.
It came up on my Google news feed just now..The company should address it somehow. It is showing up on mainstream news feeds everyone can see.
Posco Energy files for provisional attachment order against FuelCell Energy
Jan 13,2020
http://mengnews.joins.com/view.aspx?aid=3072553
If that was true they would have waited and changed the name one time to the merger company name. They just reverse split everyone, raised the AS and changed the name to some new made up, do nothing company name. Two bit nobodies ripping people off is all that happening here imho.
How much money are owed on those two notes that come due in January??? What is the dollar total??? Its a lot of money.
There is only like 200 shareholders. Even if half of them have less than 100 shares that would only cost the company $1000.
Less than 100 shares lets say 99 shares. 99 shares paid 10 cents a share is $9.99. Do that for 100 people with less than 100 shares it costs them $999
Chump change
New CEO is very impressive. Once he started getting into the technical side he really shines. Great company being born and blossoming before our eyes.
That's because bird face and Joe blow are telling the fish money is coming. All those toxic notes kick in later this week..smh
Reasons why they screwed everyone
Big RS after thwy recently raised the AS which means lots of new shares being issued.
Name change is just a new made up company not a merger with an existing quality company.
$DEAC Link to register for today's presentation
http://wsw.com/webcast/icr6/register.aspx?conf=icr6&page=draf&url=http://wsw.com/webcast/icr6/draf/index.aspx
Churchill Downs’ sportsbook brand BetAmerica is also likely to stay put in the near term, having already launched online betting with SBTech technology in three states: New Jersey, Pennsylvania and Indiana.
Churchill Downs can offer market access for DraftKings to key states like Kentucky, as well as US horse racing expertise, should DraftKings go down that route. This suggests the two firms have plenty to gain from staying connected closely.
SBTech powers Resorts’ New Jersey online sportsbook. Resorts also provides the license for DraftKings to operate in NJ and has a physical DraftKings sportsbook on the property in Atlantic City.
Given DraftKings is the second-largest operator in NJ sports betting, it’s a safe bet to assume Resorts wants that relationship to continue and will be sticking with SBTech for the foreseeable future.